

You Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5490821/publications.pdf>

Version: 2024-02-01

139
papers

4,880
citations

159525

30
h-index

114418

63
g-index

150
all docs

150
docs citations

150
times ranked

5724
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	5.1	353
2	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	15.2	322
3	Adeno-associated viruses undergo substantial evolution in primates during natural infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6081-6086.	3.3	293
4	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
5	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.784314288 /Over	0.784314288	142
6	Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. <i>Nature Medicine</i> , 2000, 6, 1160-1166.	15.2	224
7	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
8	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 437-446.	5.2	192
9	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	0.5	146
10	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 4027-4034.	0.8	141
11	Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9640-E9648.	3.3	116
12	PD-1/PD-L1 Inhibitors in Cervical Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 65.	1.6	108
13	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. <i>Lancet Oncology</i> , The, 2022, 23, 220-233.	5.1	106
14	Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2023, 115, 742-748.	3.0	99
15	Ionizing Radiation-Induced Cellular Senescence in Normal, Non-transformed Cells and the Involved DNA Damage Response: A Mini Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 522.	1.6	87
16	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	0.5	85
17	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 74-87.	0.4	82
18	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. <i>Journal of Clinical Oncology</i> , 2022, 40, 3162-3171.	0.8	76

#	ARTICLE	IF	CITATIONS
19	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2109-2120.	0.5	75
20	Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 359-370.	1.8	74
21	Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 212-224.	0.4	72
22	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	0.5	70
23	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. <i>Cancer Letters</i> , 2016, 375, 349-359.	3.2	67
24	Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. <i>Oncotarget</i> , 2016, 7, 57391-57413.	0.8	61
25	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 321-328.	0.7	61
26	Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor. <i>Journal of Immunology</i> , 2003, 170, 3162-3170.	0.4	60
27	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. <i>Nature Cancer</i> , 2022, 3, 753-767.	5.7	41
28	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	0.9	40
29	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1349-1358.	0.4	35
30	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>Tj ETQq0 0.0,rgBT /Overlock 10</i>	0.7	34
31	Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis. <i>Oncology Letters</i> , 2016, 12, 1301-1314.	0.8	33
32	Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters. <i>Radiotherapy and Oncology</i> , 2019, 132, 197-203.	0.3	33
33	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. <i>Lung Cancer</i> , 2016, 96, 93-100.	0.9	32
34	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 401-407.	0.9	31
35	Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 769-777.	0.4	31
36	Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. <i>Radiation Oncology</i> , 2014, 9, 28.	1.2	30

#	ARTICLE	IF	CITATIONS
37	Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3269-3279.	1.2	30
38	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. <i>Cancer Letters</i> , 2017, 403, 186-194.	3.2	27
39	Ethyl pyruvate alleviates radiation-induced lung injury in mice. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 468-478.	2.5	24
40	Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 505-514.	1.0	24
41	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1207-1217.	0.8	23
42	Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 1-5.	0.9	23
43	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017, 8, 111309-111317.	0.8	22
44	Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer. <i>Radiation Oncology</i> , 2014, 9, 117.	1.2	19
45	Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e43-e45.	0.5	19
46	The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1432-1441.	0.4	19
47	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 739090.	1.3	19
48	Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells. <i>Cancer Letters</i> , 2015, 365, 79-88.	3.2	18
49	Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. <i>BMC Cancer</i> , 2016, 16, 908.	1.1	18
50	Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1033-1035.	0.8	18
51	Azithromycin attenuates acute radiation-induced lung injury in mice. <i>Oncology Letters</i> , 2017, 14, 5211-5220.	0.8	18
52	Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 323-330.	3.3	18
53	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185.	0.9	18
54	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017, 8, 49680-49688.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2014, 7, 260-266.	0.8	16
56	Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations. <i>Journal of Thoracic Oncology</i> , 2016, 11, e59-e62.	0.5	16
57	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	1.4	16
58	MicroRNA Expression Profile on Solid Subtype of Invasive Lung Adenocarcinoma Reveals a Panel of Four miRNAs to Be Associated with Poor Prognosis in Chinese Patients. <i>Journal of Cancer</i> , 2016, 7, 1610-1620.	1.2	15
59	Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 147-156.	0.7	15
60	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826.	0.5	15
61	Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 529-537.	0.4	14
62	Synergy between peroxisome proliferator-activated receptor β agonist and radiotherapy in cancer. <i>Cancer Science</i> , 2018, 109, 2243-2255.	1.7	14
63	The <i>cis</i> compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2019, 20, 1097-1104.	1.5	13
64	Postoperative chemoradiotherapy improves survival in patients with stage II-III esophageal squamous cell carcinoma: An analysis of clinical outcomes. <i>Thoracic Cancer</i> , 2016, 7, 515-521.	0.8	12
65	The Association between TGF- β 1 Polymorphisms and Radiation Pneumonia in Lung Cancer Patients Treated with Definitive Radiotherapy: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e91100.	1.1	11
66	FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients. <i>Cancer Biology and Therapy</i> , 2018, 19, 76-86.	1.5	11
67	Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?. <i>Thoracic Cancer</i> , 2020, 11, 631-639.	0.8	11
68	Association between the interleukin-6 gene polymorphisms and renal cancer risk. <i>Immunology Letters</i> , 2015, 164, 125-128.	1.1	10
69	Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers. <i>CRISPR Journal</i> , 2018, 1, 47-54.	1.4	10
70	PDGFR- β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018, 99, 615-621.	2.5	10
71	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	0.9	10
72	Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. <i>Clinical Lung Cancer</i> , 2021, 22, e70-e83.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	0.6	9
74	The primary pulmonary NUT carcinomas and some uncommon somatic mutations identified by next-generation sequencing: a case report. <i>AME Case Reports</i> , 2020, 4, 24-24.	0.2	9
75	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2589-2598.	1.2	9
76	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	0.9	9
77	Fluvastatin-mediated down-regulation of SATB1 affects aggressive phenotypes of human non-small-cell lung cancer cell line H292. <i>Life Sciences</i> , 2019, 222, 212-220.	2.0	8
78	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 36.	1.1	7
79	Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 93-102.	0.6	7
80	<p>Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 647-656.	1.0	7
81	Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. <i>Lung Cancer</i> , 2021, 152, 104-108.	0.9	7
82	Large-scale molecular epidemiological analysis of AAV in a cancer patient population. <i>Oncogene</i> , 2021, 40, 3060-3071.	2.6	7
83	Phase 3 study of first-line crizotinib vs pemetrexed+ cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i>+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058.	0.8	7
84	Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. <i>Oncotarget</i> , 2016, 7, 66480-66490.	0.8	7
85	Expression analysis of the estrogen receptor target genes in renal cell carcinoma. <i>Molecular Medicine Reports</i> , 2015, 11, 75-82.	1.1	6
86	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. <i>Journal of Thoracic Disease</i> , 2020, 12, 639-650.	0.6	6
87	Secondary infections after diagnosis of severe radiation pneumonitis (SRP) among non-small cell lung cancer patients: pathogen distributions, choice of empirical antibiotics and the value of empirical antifungal treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	6
88	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 448-466.	0.7	6
89	Phase <sc>II</sc> study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an <sc>EP</sc> regimen. <i>Thoracic Cancer</i> , 2013, 4, 234-240.	0.8	5
90	The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model. <i>Inflammation</i> , 2017, 40, 1254-1263.	1.7	5

#	ARTICLE	IF	CITATIONS
91	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. <i>Investigational New Drugs</i> , 2020, 38, 478-484.	1.2	5
92	Salvage treatment with erlotinib after gefitinib failure in advanced non-small cell lung cancer patients with poor performance status: A matched-pair case-control study. <i>Thoracic Cancer</i> , 2012, 3, 27-33.	0.8	4
93	Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multicenter prospective study. <i>Thoracic Cancer</i> , 2013, 4, 14-19.	0.8	4
94	Dosimetric effect of beam arrangement for intensity-modulated radiation therapy in the treatment of upper thoracic esophageal carcinoma. <i>Medical Dosimetry</i> , 2017, 42, 47-52.	0.4	4
95	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	0.8	4
96	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100131.	0.6	4
97	Pseudo-small cell transformation in EGFR-mutant adenocarcinoma. <i>Lung Cancer</i> , 2021, 153, 120-125.	0.9	4
98	Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 149-149.	0.7	4
99	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
100	Differential diagnosis of acute miliary pulmonary tuberculosis from widespread-metastatic cancer for postoperative lung cancer patients: two cases. <i>Journal of Thoracic Disease</i> , 2017, 9, E115-E120.	0.6	3
101	Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 421-426.	0.7	3
102	Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 1221-1229.	0.3	3
103	A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2021, , 1.	1.2	3
104	Novel mutation in the <i>ASXL3</i> gene in a Chinese boy with microcephaly and speech impairment: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 6465-6472.	0.3	3
105	Clinicopathologic Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	3
106	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20611-e20611.	0.8	3
107	Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 567-570.	0.4	2
108	Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?. <i>International Journal of Clinical Oncology</i> , 2018, 23, 258-265.	1.0	2

#	ARTICLE	IF	CITATIONS
109	T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report. <i>Precision Clinical Medicine</i> , 2018, 1, 129-133.	1.3	2
110	Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lungâ€molGPA) in a Chinese cohort: A retrospective study of multiple institutions. <i>Cancer Medicine</i> , 2020, 9, 8772-8781.	1.3	2
111	PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. <i>Scientific Reports</i> , 2020, 10, 16150.	1.6	2
112	Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1072-1083.	1.0	2
113	Marvelous objective response of low dose radiotherapy plus ICIs for extended stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21097-e21097.	0.8	2
114	Alveolar rhabdomyosarcoma of nasopharynx and paranasal sinuses with metastasis to breast in a middle-aged woman: a case report and literature review. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 15316-21.	0.5	2
115	Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 780956.	1.2	2
116	A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic nonâ€small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9027-9027.	0.8	2
117	Targeting YAP Acetylation in Cancer. <i>Journal of Biological Chemistry</i> , 2012, 287, 35442.	1.6	1
118	Cancer screening education in Chinese medical schools. <i>Lancet Oncology</i> , The, 2014, 15, e300-e301.	5.1	1
119	Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. <i>Frontiers in Oncology</i> , 2020, 10, 573512.	1.3	1
120	Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention (EMT-OCSP): a protocol for a pragmatic, multicentre, observer-blinded, 12-month randomised controlled study. <i>BMJ Open</i> , 2021, 11, e043450.	0.8	1
121	Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20543-e20543.	0.8	1
122	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9077-9077.	0.8	1
123	SNAILs promote G1 phase in selected cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 1863-73.	1.4	0
124	Negative pathology of ureteral carcinoma significantly delaying the diagnosis of the primary tumor of osteoblastic metastases: A case report and review of the literature. <i>Oncology Letters</i> , 2016, 12, 2417-2420.	0.8	0
125	Reply to A. Chalmers et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2341-2341.	0.8	0
126	Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21131-e21131.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Endostar plus gemcitabine/cisplatin (GP) with maintenance endostar as first-line therapy for advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study.. Journal of Clinical Oncology, 2012, 30, e18033-e18033.	0.8	0
128	Safety and efficacy of paclitaxel liposome monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer: A prospective, multicenter, uncontrolled phase II study.. Journal of Clinical Oncology, 2012, 30, e18086-e18086.	0.8	0
129	Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.. Journal of Clinical Oncology, 2012, 30, 4073-4073.	0.8	0
130	Phase I study of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases: neurocognitive and quality-of-life analysis.. Journal of Clinical Oncology, 2016, 34, e20009-e20009.	0.8	0
131	Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy.. Journal of Clinical Oncology, 2017, 35, TPS9104-TPS9104.	0.8	0
132	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation? A bicenter research and pooled analysis of published reports.. Journal of Clinical Oncology, 2017, 35, e20571-e20571.	0.8	0
133	Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 2131-2136.	0.9	0
134	Why aren't we getting consistent results for heart dose and mortality during thoracic radiotherapy?. Annals of Translational Medicine, 2020, 8, 1252.	0.7	0
135	Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).. Journal of Clinical Oncology, 2022, 40, e21174-e21174.	0.8	0
136	Striking effect of low-dose radiotherapy combined with PD-1 blockade on small cell lung cancer in mice and refractory patients (Achilles Study).. Journal of Clinical Oncology, 2022, 40, e20608-e20608.	0.8	0
137	Abstract CT510: A phase I clinical trial of 3D-pluripotent stem cell biologics in heavily treated advanced NSCLC patients. Cancer Research, 2022, 82, CT510-CT510.	0.4	0
138	Abstract 5569: CAR-T cells with $\hat{\pm}$ PDL1/CD28 switch-receptor synergize radiotherapy and anti-PD1 therapy in solid tumors. Cancer Research, 2022, 82, 5569-5569.	0.4	0
139	Linkage of time interval from neoadjuvant chemoradiotherapy to surgery with pathological response and survival profile in resectable esophageal cancer patients.. Journal of Clinical Oncology, 2022, 40, e16071-e16071.	0.8	0